ANEBULO PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)

Item 2.02 Results of Operations and Financial Condition

On January 9, 2023, Anebulo Pharmaceuticals, Inc. (the "Company") announced in its corporate presentation that as of December 31, 2022 it had $16 million in cash which is expected to provide a cash runway into 2024.

The information in this Item 2.02 of this Current Report on 8-K is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today's date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Item 7.01 Regulation FD Disclosure.

On January 9, 2023, the Company updated its corporate slide presentation for use in meetings with investors, analysts and others. The presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information in this Item 7.01 of this Current Report on 8-K (including Exhibit 99.1) is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today's date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Item 8.01 Other Events.

On January 9, 2023, the Company issued a press release titled, "Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication." The press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


Exhibit
Number                                  Description
 99.1       Company Presentation dated January 2023
            Press Release of Anebulo Pharmaceuticals, Inc., dated January 9,
 99.2     2023
          Cover Page of Interactive Data File (embedded within the Inline XBRL
  104     document).

© Edgar Online, source Glimpses